Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEHAWNYSE:AMPENASDAQ:CALANASDAQ:ODT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEHAWAesther Healthcare Acquisition$0.01$0.01$0.06▼$0.33N/AN/A34,287 shs30,000 shsAMPEAmpio Pharmaceuticals$0.02$0.00▼$0.45N/A4.76600 shs45 shsCALACalithera Biosciences$0.00$0.00▼$0.05N/A-2.8213,914 shs5 shsODTOdonate Therapeutics$1.27$0.85▼$7.10N/AN/AN/A87,682 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEHAWAesther Healthcare Acquisition0.00%-8.70%+30.43%-61.64%-80.94%AMPEAmpio Pharmaceuticals0.00%-96.30%-99.92%-83.33%-99.90%CALACalithera Biosciences0.00%0.00%-95.00%-83.33%-99.00%ODTOdonate Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AAMPEAmpio Pharmaceuticals0.053 of 5 stars0.03.00.00.00.00.00.0CALACalithera BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AODTOdonate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEHAWAesther Healthcare Acquisition 0.00N/AN/AN/AAMPEAmpio Pharmaceuticals 0.00N/AN/AN/ACALACalithera Biosciences 0.00N/AN/AN/AODTOdonate Therapeutics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AAMPEAmpio PharmaceuticalsN/AN/AN/AN/A$4.04 per shareN/ACALACalithera BiosciencesN/AN/AN/AN/AN/AN/AODTOdonate TherapeuticsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEHAWAesther Healthcare AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AAMPEAmpio Pharmaceuticals-$8.63M-$11.01N/AN/AN/AN/AN/AN/AN/ACALACalithera Biosciences-$39.65MN/A0.00N/AN/AN/AN/AN/AN/AODTOdonate Therapeutics-$126.35MN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AAMPEAmpio PharmaceuticalsN/AN/AN/AN/AN/ACALACalithera BiosciencesN/AN/AN/AN/AN/AODTOdonate TherapeuticsN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEHAWAesther Healthcare AcquisitionN/AAMPEAmpio Pharmaceuticals5.73%CALACalithera BiosciencesN/AODTOdonate TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipAEHAWAesther Healthcare AcquisitionN/AAMPEAmpio Pharmaceuticals3.30%CALACalithera Biosciences6.60%ODTOdonate Therapeutics48.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEHAWAesther Healthcare Acquisition2N/AN/ANot OptionableAMPEAmpio Pharmaceuticals201.14 million1.10 millionNo DataCALACalithera Biosciences604.87 million4.55 millionNot OptionableODTOdonate Therapeutics14528.53 million14.58 millionNot OptionableODT, AEHAW, AMPE, and CALA HeadlinesRecent News About These CompaniesRoche Completes $2.7B Acquisition of Carmot TherapeuticsJuly 30, 2024 | contractpharma.comCOdonate Inc ODTCJuly 28, 2024 | morningstar.comMProQR Therapeutics NV (PRQR)February 6, 2024 | investing.comVitamin D signalling pathways in cancer: potential for anticancer therapeuticsJune 20, 2023 | nature.comNOrally Disintegrating Tablet (ODT) Market 2023 | Future Exploration by 2030March 29, 2023 | marketwatch.comPfizer recalls migraine drug Nurtec ODT after millions of products lacked child resistant packagingMarch 19, 2023 | usatoday.comFate Therapeutics Stock (NASDAQ:FATE), Analyst Ratings, Price Targets, PredictionsMarch 3, 2023 | benzinga.comOrally Disintegrating Tablet (ODT) Market Size 2023 with Big Company Segment, Cost-Effective Solutions Analysis Information 2029January 30, 2023 | marketwatch.comViking Therapeutics accuses competitor of pilfering proprietary informationJanuary 14, 2023 | cen.acs.orgCODTC Odonate Therapeutics, Inc.October 22, 2022 | seekingalpha.comOdonate TherapeuticsSeptember 14, 2022 | forbes.comWe Just Learned Something New! After Odonate Therapeutics Inc. (NASDAQ: ODT)’s -2.63% Loss This WeekDecember 18, 2021 | marketingsentinel.comMODONATE INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Odonate Therapeutics, Inc. - ODTDecember 10, 2021 | finance.yahoo.comOdonate Therapeutics Inc. (NASDAQ: ODT) Stock Forecast 2021: Profitable With Bullish SignalsNovember 23, 2021 | marketingsentinel.comMOdonate Therapeutics Insider Sold Over $2.5M In Company StockNovember 22, 2021 | finance.yahoo.comVolatility Hits 15.98% At Odonate Therapeutics Inc. (ODT) – Here’s What A Good Investor Should DoNovember 18, 2021 | stocksregister.comSOdonate Therapeutics Inc. (NASDAQ: ODT): At Current Prices, Does It Make Sense To Wait?November 18, 2021 | marketingsentinel.comMOdonate Therapeutics, Inc. (ODT)October 27, 2021 | uk.finance.yahoo.comDoes Odonate Therapeutics Inc. (NASDAQ:ODT) Look Expensive At $3.05? Here’s How To Know.October 2, 2021 | marketingsentinel.comMOne Odonate Therapeutics, Inc. (NASDAQ:ODT) insider upped their stake in the previous yearSeptember 27, 2021 | nasdaq.comNew MarketBeat Followers Over TimeODT, AEHAW, AMPE, and CALA Company DescriptionsAesther Healthcare Acquisition NASDAQ:AEHAW$0.0091 0.00 (0.00%) As of 07/3/2025Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.Ampio Pharmaceuticals NYSE:AMPEAmpio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.Calithera Biosciences NASDAQ:CALACalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.Odonate Therapeutics NASDAQ:ODTOdonate Therapeutics is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several potential therapeutic advantages over currently available taxanes, including: oral administration with a low pill burden and a patient-friendly dosing regimen; a formulation that does not contain solubilizing agents that are known to cause hypersensitivity (allergic) reactions; and improved activity against chemotherapy-resistant tumors. Tesetaxel has been generally well tolerated in clinical studies and has demonstrated robust single-agent antitumor activity in two Phase 2 studies in patients with locally advanced or metastatic breast cancer (''MBC''). More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
